News

MOVANO HEALTH CLOSES $24 MILLION PRIVATE PLACEMENT

PLEASANTON, Calif., April 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, has closed on a $24.1 million private placement, totaling 45.3 million units, with each unit consisting of one share of the Company's common stock (or...

read more

ETON PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING

DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously...

read more

MOVANO INC. CLOSES BRIDGE FINANCING ROUND AT $12.5M

After announcing $10M in bridge funding in July, the company raised an additional $2.5M to progress the development of its wearable non-invasive continuous glucose monitor PLEASANTON, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) — Movano Inc., a health-focused technology...

read more

ATOMERA ANNOUNCES CLOSING OF PUBLIC OFFERING

Underwriter Exercises Its Overallotment Option in Full LOS GATOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and intellectual property licensingcompany focused on deploying its proprietary technology into the...

read more

CROSSCODE, INC. ANNOUNCES $9.25 MILLION SERIES A FINANCING

MAPLE GROVE, Minn., May 28, 2019 /PRNewswire/ — Crosscode, Inc, an enterprise software development company that focuses on helping companies manage their software assets, today announced that it recently closed a $9.25 million private placement of Series A preferred...

read more

ATOMERA ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK

LOS GATOS, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) — Atomera Incorporated (Nasdaq: ATOM) today announced the closing of its previously announced underwritten public offering of 2,625,000 shares of common stock at a public offering price of $4.75 per share.  Atomera has...

read more

ETON PHARMACEUTICALS ANNOUNCES $20 MILLION SERIES A FINANCING

Proceeds to support the development of Eton’s proprietary corticotropin product candidate, Peyronie’s Disease product candidate and other sterile injectable product candidates CHICAGO and SAN DIEGO, June 20, 2017 /PRNewswire/ — Eton Pharmaceuticals, Inc., a spin-out...

read more

IDEAL POWER ANNOUNCES $15 MILLION PRIVATE PLACEMENT

AUSTIN, TX–(Feb 27, 2017) – Ideal Power Inc. (NASDAQ: IPWR), a developer of innovative power conversion technologies, has entered into a definitive securities purchase agreement with various accredited investors, including all of Ideal Power’s executive officers and...

read more

RESONANT PRICES UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Goleta, Calif.– Resonant Inc. (NASDAQ: RESN), a designer of filters for radio frequency, or RF, front-ends that specializes in delivering designs for difficult bands and complex requirements, today announced the pricing of an underwritten public offering of 2,360,870...

read more

ATOMERA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

LOS GATOS, CA – August 4, 2016 – Atomera, Incorporated (NASDAQ: ATMR), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the $350+ billion semiconductor industry, today announced the pricing of...

read more

AQUA METALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

OAKLAND, CA – July 30, 2015 – Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a developer of an electrochemical lead recycling technology, today announced the pricing of its initial public offering of 6,600,000 shares of common stock at a public...

read more

ENERGOUS CLOSES PUBLIC OFFERING OF COMMON STOCK

SAN JOSE, CA – December 15, 2014 – Energous Corporation (“Energous”) (WATT), today announced that it has completed its previously announced underwritten public offering of its common stock at a price of $7.00 per share to the public. Due to the exercise in full of the...

read more

335 Spruce Avenue

Ketchum, ID 83340

310 305 3085

All securities offered through  The Benchmark Company, LLC, Member FINRA  anSIPC.  Liquid Venture Partners, LLC and The Benchmark Company, LLC are independent entities.  Officers of Liquid Venture Partners, LLC are licensed registered representatives of The Benchmark Company, LLC.  Nothing on this website should be considered an offer to sell or the solicitation of an offer to buy shares of any security.  This site is not intended to offer investment advice.  Companies listed under the Investment section are subject to change and updated quarterly.  

Important Consumer Information: This communication is strictly intended for individuals residing in the states of AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, KY, LA, MA, MD, MI, MN, MO, NC, NH, NJ, NM, NV, NY, OH, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WY. No offers will be made or accepted from any resident outside the specific state(s) referenced.